Relay Therapeutics, Inc. Relay Therapeutics, Inc.

Relay Therapeutics, Inc.

RLAY

Ранг среди акций #4387
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Цена акции
$16.24
Последняя синхронизация: 2026-10-16
Рыночная капитализация
$3.56B
Изменение (1 день)
-6.13%
Изменение (1 год)
150.23%
Страна
US
Торговля Relay Therapeutics, Inc. (RLAY)

Категория

Healthcare
EPS для Relay Therapeutics, Inc. (RLAY)
EPS по состоянию на June 2026 TTM: $-1.57
Согласно последним финансовым отчетам и цене акций Relay Therapeutics, Inc., текущий EPS компании (TTM) составляет $-1.57. В конце 2023 EPS компании составлял $-2.79, больше, чем показателю 2022 года, равному $-2.59.
История EPS компании Relay Therapeutics, Inc. с 2018 по 2026
EPS на конец каждого года
Год EPS Изменить
2026 (TTM) $-1.57 -33.47%
2024 $-2.36 -15.41%
2023 $-2.79 7.72%
2022 $-2.59 -32.20%
2021 $-3.82 49.22%
2020 $-2.56 -83.52%
2019 $-15.53 -20.89%
2018 $-19.63 0.00%
EPS для аналогичных компаний или конкурентов
Компания EPS Разница в EPS Страна
$17.32 -1,203.18%
US
$-7.98 408.28%
US
$-5.29 236.94%
AU
- -
CH
$27.74 -1,866.88%
NL